StonvexLoading…
StonvexStonvexStonvexCore line items from CRK's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $587.35M | $2.22B | $1.43B | $983.12M |
Operating Income | $174.89M | $645.85M | $265.83M | $215.61M |
Net Income | $107.45M | $395.61M | $114.69M | $3.56M |
EPS (Diluted) | $0.38 | $1.43 | $0.45 | $0.05 |
Total Assets | $7.24B | $7.01B | $6.84B | $6.69B |
Total Liabilities | $4.17B | $4.04B | $4.22B | $4.26B |
Cash & Equivalents | $14.79M | $23.93M | $19.21M | $25.86M |
Free Cash Flow OCF − CapEx | $-143.85M | $-449.67M | $-308.43M | $-120.02M |
Shares Outstanding | 293.70M | 293.05M | 293.05M | 293.07M |